

03/13/00  
JC 780 U.S. PTO

3-14-00 A

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 6475.US.O2

First Inventor or Application Identifier Jitendra P. Patel

Title Novel Formulations Comprising Lipid-Regulating Agents

Express Mail Label No. EL507363175US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2.  Specification [Total Pages 11]
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3.  Drawing(s) (35 U.S.C. 113) [Total Sheets 1]
4. Oath or Declaration [Total Pages ]
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
    - i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

\* NOTE FOR ITEMS 1 & 13 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

5.  Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a.  Computer Readable Copy
  - b.  Paper Copy (identical to computer copy)
  - c.  Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

7.  Assignment Papers (cover sheet & document(s))
8.  37 C.F.R. § 3.73(b) Statement  Power of (when there is an assignee)  Attorney
9.  English Translation Document (if applicable)
10.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations
11.  Preliminary Amendment
12.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
13.  Small Entity Statement(s)  Statement filed in prior application (PTO/SB/09-12)  Status still proper and desired
14.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
15.  Other: Unexecuted Oath and POA  
.....

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No. /  
Prior application information: Examiner Group / Art Unit

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 17. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label  (Insert Customer No. or Attach bar code label here) or  Correspondence address below

Name Steven F. Weinstock

Abbott Laboratories

Address D377/AP6D-2

100 Abbott Park Road

City Abbott Park State IL Zip Code 60064-6050

Country Telephone (837) 937-8272 Fax (847) 938-2623

Name (Print/Type) Dugal S. Sickert

Registration No. (Attorney/Agent)

33,784

Signature

Date

3/13/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

Novel Formulations Comprising Lipid-Regulating Agents

Reference to Related Application

5        This application is a conversion of United States  
Provisional Patent Application 60/127,136, filed on March  
31, 1999.

10      Field of the Invention

The present invention relates to novel formulations comprising lipid-regulating agents.

15      Background of the Invention

20      2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Patent No. 4,058,552.

25      Fenofibrate has been prepared in several different formulations, c.f., U.S. Patent No. 4,800,079 and U.S. Patent No. 4,895,726. U.S. Patent No. 4,895,726 discloses a co-micronized formulation of fenofibrate and a solid surfactant.

30      U.S. Patent No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix. The formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said

dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed.

5

European Patent Application No. EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granulate thus produced is dried.

10

PCT Publication No. WO 82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch. The neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.

20

25

25 surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.

30

35

Gemfibrozil is another member of the fibrate class of lipid-regulating agents. U.S. Patent No. 4,927,639 discloses a disintegratable formulation of gemfibrozil providing both immediate and sustained release, comprising a tablet compressed from a mixture of a first and second granulation, and a disintegration excipient operable to effect partial or complete disintegration in the stomach. The first

granulation comprises finely divided particles of pure gemfibrozil granulated with at least one cellulose derivative, and the second granulation comprises finely divided particles of pure gemfibrozil granulated with a pharmaceutically-acceptable water soluble or insoluble polymer which are then uniformly coated with a pharmaceutically-acceptable (meth)acrylate copolymer prior to admixture with the first granulation. The first and second granulations are present in the final composition in a ratio of from about 10:1 to about 1:10.

U.S. Patent 4,925,676 discloses a disintegratable gemfibrozil tablet providing both immediate and enteric release, which is compressed from a mixture of a first granulation of gemfibrozil with at least one acid-disintegratable binder, and a second granulation formed from the first granulation, but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid-insoluble polymer.

Another class of lipid-regulating agents are commonly known as statins, of which pravastatin and atorvastatin are members. U.S. Patents 5,030,447 and 5,180,589 describe stable pharmaceutical compositions, which when dispersed in water have a pH of at least 9, and include a medicament which is sensitive to a low pH environment, such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.

It is an object of the present invention to provide formulations of lipid-regulating agents having enhanced

bioavailability and longer half-life when compared to commercially available formulations.

5

### Summary of the Invention

10

The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in an oil, with subsequent emulsification using one or more emulsifiers. This formulation forms fine and stable emulsions. The emulsions result in an increase in drug solubility, oral bioavailability and half-life.

15

The formulation may be administered directly, diluted into an appropriate vehicle for administration, encapsulated into soft or hard gelatin shells or capsules for administration, or administered by other means obvious to those skilled in the art.

20

### Brief Description of the Drawings

25

Figure 1 is a graph showing the plasma concentration in fasted dogs of the formulation of Example 1 and a reference compound.

### Detailed Description of the Invention

30

The bulk lipid-regulating agent may be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Patent No. 4,058,552, or the procedure disclosed in U.S. Patent No. 4,739,101, both herein incorporated by reference.

35

The solution comprising the lipid-regulating agent is prepared by dissolving said agent in the oil with adequate

mixing. An emulsifier or emulsifier blend is added to said mixture and mixed until uniform. If desired, water can be then added to the resulting mixture with agitation to form a uniform emulsion.

5

The delivery system of the present invention results in increased solubility, half-life and bioavailability of the lipid-regulating agent. It can be further diluted with additional liquids or it may be thickened and/or stabilized 10 with various pharmaceutical excipients to vary its existing properties.

10

Suitable oils include, but are not limited to, any pharmaceutically acceptable oil, such as, for example, soybean oil, coconut oil, canola oil, corn oil, palm kernel oil, cottonseed oil, olive oil, peanut oil, safflower oil and sesame oil.

15

Suitable emulsifiers include any pharmaceutically acceptable hydrophilic or lipophilic emulsifier or combinations thereof, such as, for example, phospholipids, polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives, polyoxyl-35-castor oil (Cremophor EL, available from BASF), castor oil or hydrogenated castor 20 oil ethoxylates, polyglycerol esters of fatty acids, fatty acid ethoxylates, alcohol ethoxylates, polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, and TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate). Preferred emulsifiers include polyoxyethylene sorbitan fatty 25 acid derivatives, sorbitan fatty acid derivatives and polyoxyl-35-castor oil (Cremophor EL, available from BASF).

20

Preferred emulsifiers include polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives and polyoxyl-35-castor oil (Cremophor EL, available from BASF).

25

Other optional ingredients which may be included in the compositions of the present invention are those which are conventionally used in oil-based drug delivery systems, e.g. 30 antioxidants such as, for example, tocopherol, ascorbyl palmitate, ascorbic acid, butylated hydroxytoluene,

30

35

butylated hydroxyanisole, propyl gallate, etc.; pH stabilizers such as, for example, citric acid, tartaric acid, fumaric acid, acetic acid, glycine, arginine, lysine, potassium hydrogen phosphate, etc.; thickeners/suspending agents such as, for example, hydrogenated vegetable oils, beeswax, colloidal silicon dioxide, gums, celluloses, silicates, bentonite, etc.; flavoring agents such as, for example, cherry, lemon, aniseed flavors, etc.; sweeteners such as, for example, aspartame, saccharin, cyclamates, etc.; and co-solvents, such as, for example, ethanol, propylene glycol, polyethylene glycol, dimethyl isosorbide, etc.

The resulting liquid comprising the lipid-regulating agent may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into soft or hard shells or capsules for oral administration, or delivered by some other means obvious to those skilled in the art. The said liquid can be used to improve the oral bioavailability, and increase the half-life and solubility of said lipid-regulating agent.

The invention will be understood more clearly from the following non-limiting representative examples:

25

Example 1

SR Soybean oil (24.33 g) was added to a beaker and fenofibrate (0.67 g) was dissolved in it by stirring. Sorbitan monooleate (2.5 g) was added to the beaker and mixed until uniform. Polysorbate 80 (0.5 g) was then added and mixed until uniform. Finally water (72 g) was added slowly with constant mixing until a uniform emulsion resulted.

Example 2

5 SR Soybean oil (24 g) is added to a beaker and pravastatin (1 g) is dispersed in it by stirring. Sorbitan monooleate (2.5 g) is added to the beaker and mixed until uniform. Polysorbate 80 (0.5 g) is then added and mixed until uniform. Finally water (72 g) is added slowly with constant mixing until a uniform emulsion resulted.

10

Example 3

15 SR Soybean oil (24 g) is added to a beaker and atorvastatin (1 g) is dispersed in it by stirring. Sorbitan monooleate (2.5 g) is added to the beaker and mixed until uniform. Polysorbate 80 (0.5 g) is then added and mixed until uniform. Finally water (72 g) is added slowly with constant mixing until a uniform emulsion resulted.

20

Example 4

25 The emulsion prepared by the process described in Example 1, and from a commercial fenofibrate composition, Lipanthyl 67M (Groupe Fournier) (Reference), were administered to a group of dogs at a dose of 67 mg fenofibrate/dog (10 mL emulsion or one capsule/dog). The plasma concentrations of fenofibric acid were determined by HPLC. Concentrations were normalized to a 6.7 mg/kg dose in each dog. Figure 1 presents the resulting data in graph form. The results provided as mean  $\pm$  SD, n=6, were as follows:

100-  
90-  
80-  
70-  
60-  
50-  
40-  
30-  
20-  
10-  
0-

Lipanthyl 67M (Reference) :

Cmax = 1.88 ± 0.97 mcg/ml

Tmax = 1.6 ± 0.9 hr

t<sub>1/2</sub> = 4.5 hr

5 AUC (0-24) = 11.08 ± 9.42 mcg•hr/ml

Emulsion of Example 1:

Cmax = 4.97 ± 3.13 mcg/ml

Tmax = 1.1 ± 0.5 hr

10 t<sub>1/2</sub> = 7.8 hr

AUC (0-24) = 24.21 ± 11.69 mcg•hr/ml

AUC relative to Reference = 2.2

Claims

1. A composition comprising a lipid-regulating agent dissolved or dispersed in at least one oil with one or more emulsifiers, wherein the mixture is capable of forming an emulsion upon dilution with an aqueous phase.
2. A composition of claim 1 wherein said lipid-regulating agent is a fibrate.
3. A composition of claim 2 wherein said fibrate is fenofibrate.
4. A composition of claim 1 wherein said lipid-regulating agent is a statin.
5. A composition of claim 4 wherein said statin is pravastatin.
6. A composition of claim 4 wherein said statin is atorvastatin.
7. A composition of claim 1 wherein at least one or more of said emulsifiers is selected from phospholipids, polyoxyethylene sorbitan fatty acid derivatives, sorbitan fatty acid derivatives, Polyoxy-35-castor oil (Cremophor EL, available from BASF), castor oil or hydrogenated castor oil ethoxylates, polyglycerol esters of fatty acids, fatty acid ethoxylates, alcohol ethoxylates, polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, and TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate).
8. A composition of claim 7 wherein at least one or more of said emulsifiers is polyoxyethylene sorbitan fatty

acid derivatives, sorbitan fatty acid derivatives and polyoxyl-35-castor oil.

9. A composition of claim 1 wherein said oil is selected from soybean oil, coconut oil, canola oil, corn oil, palm kernel oil, cottonseed oil, olive oil, peanut oil, safflower oil and sesame oil.

10. A composition of claim 9 wherein said oil is soybean oil.

11. A composition of claim 1 further comprising a co-solvent.

12. A composition of claim 11 wherein said co-solvent is ethanol, propylene glycol or polyethylene glycol.

13. A delivery system comprising a composition of claim 1.

20 14. A delivery system of claim 13 wherein said delivery system is an emulsion.

15 15. A delivery system of claim 13 wherein said delivery system is a capsule.

25 16. A method of treating hyperlipidemia comprising the administration of a composition of claim 1 to a patient.


30 17. A method of treating hyperlipidemia comprising the administration of a composition of claim 3 to a patient.

35 18. A method of treating hyperlipidemia comprising the administration of a composition of claim 14 to a patient.

Abstract of the Disclosure

The present invention is directed to a formulation comprising a lipid-regulating agent dissolved or dispersed in at least one oil and an emulsifier or emulsifier blend, the resulting mixture being capable of forming an emulsion upon dilution in an aqueous medium.

FIGURE 1



**PATENT**  
**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

APPLICANT: J. Patel, et al.	Express Mail No.: EL507363175US
SERIAL NO.: not yet assigned	I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as U.S. Express Mail, Post Office to Addressee Service under 37 C.F.R. 1.10 addressed to:
FILED: March 13, 2000	Box Patent Application
FOR: NOVEL FORMULATIONS COMPRISING LIPID- REGULATING AGENTS	Assistant Commissioner for Patents
EXAMINER: (not yet assigned)	Washington, D.C.
CASE NO.: 6475.US.O2	Date of Deposit: March 13, 2000
GROUP ART UNIT: (not yet assigned)	<u>Karina Limon</u> 3/13/00
DATE: March 13, 2000	Karina Limon Date

**DECLARATION AND POWER OF ATTORNEY  
FOR A UNITED STATES PATENT APPLICATION**

As a below-named inventor, I hereby declare:

My residence, post office address and citizenship are as stated below next to my name. I believe I am an original and first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled NOVEL FORMULATIONS COMPRISING LIPID-REGULATING AGENTS, the specification of which is attached.

I hereby state that I have reviewed and understand the contents of the above-mentioned specification, including the claims.

I acknowledge a duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, 1.56.

Claim to benefit of foreign application(s) as follows:

I hereby claim foreign priority benefits under 35 U.S.C. '119 for the following foreign applications for patent or inventors certificate.

NONE

The following foreign applications for patent or inventor's certificate have a filing date earlier than the filing date of the applications identified above.

NONE

Claim to benefit of earlier U.S. application(s) as follows:

I hereby claim the benefit under 35 U.S.C.'120 of the following earlier-filed United States patent applications. Insofar as the subject matter of each of the claims of this application is not disclosed in the prior U.S. applications in the manner required by 35 U.S.C. '112, first paragraph, I acknowledge a duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. '1.56 which came into existence between the filing date(s) of the prior applications and the national or PCT filing date of this application.

NONE

I hereby claim the benefit under Title 35, United States Code '119(e) of any United States provisional application(s) listed below:

Serial No. 60/127,136, filed March 31, 1999

I hereby appoint the following Attorneys and/or agents to prosecute this application and any continuation or divisional applications based hereon, and to transact all business in the Patent and Trademark Office connected therewith:

Regina M. Anderson, Reg. No. 35,820  
Cheryl L. Becker, Reg. No. 35,441  
Thomas D. Brainard, Reg. No. 32,459  
Dianne Casuto, Reg. No. 40,943  
Steven R. Crowley, Reg. No. 31,604  
Andreas M. Danckers, Reg. No. 32,652  
J. Michael Dixon, Reg. No. 32,410  
Mimi C. Goller, Reg. No. 39,046  
Daniel J. Hulseberg, Reg. No. 36,554  
Neal D. Marcus, Reg. No. 35,267  
Robert A. Miller, Reg. No. 26,956

James D. McNeil, Reg. No. 26,204  
Lawrence S. Pope, Reg. No. 26,791  
Nicholas A. Poulos, Reg. No. 30,209  
Dugal S. Sickert, Reg. No. 33,784  
Gregory W. Steele, Reg. No. 33,796  
Michael J. Ward, Reg. No. 37,960  
David L. Weinstein, Reg. No. 28,128  
Steven F. Weinstock, Reg. No. 30,117  
Brian R. Woodworth, Reg. No. 33,137  
Paul D. Yasger, Reg. No. 37,477

Send Correspondence to:

Steven F. Weinstock  
Abbott Laboratories  
D-377/AP6D  
100 Abbott Park Road  
Abbott Park, IL 60064-6050

Direct telephone calls to:

Dugal S. Sickert  
(847) 937-8272

Name:  
Post Office Address:  
Residence:  
Citizenship:

Jitendra P. Patel  
Libertyville, IL 60048  
1105 Ashbury Lane, Libertyville, IL 60048  
India

Name:  
Post Office Address:  
Residence:  
Citizenship:

Yeshwant D. Sanzgiri  
Gurnee, IL 60031  
1323 Deer Run, Gurnee, IL 60031  
India

Name:  
Post Office Address:  
Residence:  
Citizenship:

John M. Lipari  
Racine, WI 53406  
6600 Apollo Drive, Racine, WI 53406  
United States of America

Name:  
Post Office Address:  
Residence:  
Citizenship:

Thomas L. Reinland  
Gages Lake, IL 60030  
33974 N. Lake Shore Drive, Gages Lake, IL 60030  
United States of America

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that all statements made herein were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

---

Jitendra P. Patel

Date

---

Yeshwant D. Sanzgiri

Date

---

John M. Lipari

Date

---

Thomas L. Reiland

Date